s20098 has been researched along with Depression, Endogenous in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (24.19) | 29.6817 |
| 2010's | 45 (72.58) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| An, Q; Chen, Y; Li, C; Li, J; Luo, Y; Song, R; Tong, A; Yang, Y; Zhou, L | 1 |
| Uvais, NA | 1 |
| Allaïli, N; Euvrard, M; Fossati, P; Franc, B; Gabriel, C; Lanfumey, L; Lehericy, S; Marday, T; Martin, V; Mocaër, E; Riffaud, A | 1 |
| Baus, C; Dogui, R; Kennel, J; Riemenschneider, M; Siebert, S | 1 |
| Ilias, I; Karaiskos, D; Liappas, I; Paparrigopoulos, T; Tzavellas, E | 1 |
| Corruble, E; Demyttenaere, K; Hale, A; Kasper, S; Picarel-Blanchot, F; Quera-Salva, MA | 1 |
| Norman, TR | 1 |
| Strashunskaya, EL; Strashunskaya, EY | 1 |
| Tan, HL | 1 |
| Corbach-Söhle, S; Flügge, G; Fuchs, E; Kohlhause, S; Schlumbohm, C; Schmelting, B | 1 |
| Soldatkin, VA | 1 |
| Emtsov, KG; Panova, NB; Popova, YV; Pribytkov, AA | 1 |
| Calandre, EP; Garcia-Leiva, JM; Rico-Villademoros, F; Rodriguez-Lopez, CM; Slim, M; Torres, P | 1 |
| Almeida, OF; Alves, ND; Beckers, J; Bessa, JM; Correia, JS; Irmler, M; Korostynski, M; Machado-Santos, AR; Mateus-Pinheiro, A; Morais, M; Patrício, P; Piechota, M; Pinto, L; Sousa, N; Stoffel, R | 1 |
| Harvey, BH; Slabbert, FN | 1 |
| Becker, T; Kösters, M; Staudigl, L | 1 |
| Baylé, F; Cléry-Melin, ML; Cléry-Melun, ML; Gorwood, P; Richard-Devantoy, S | 1 |
| Bumgardner, AL; Fadel, JR; Gabriel, C; Grillo, CA; Hang, A; Macht, VA; Mocaër, E; Piroli, GG; Reagan, LP; Risher, M | 1 |
| Gavrilova, SI; Kolykhalov, IV; Ponomareva, EV; Selezneva, ND | 1 |
| Campanella, D; De Bartolomeis, A; De Berardis, D; Di Giannantonio, M; Di Nicola, M; Fornaro, M; Iasevoli, F; Martinotti, G; Mazza, M; Olivieri, L; Perna, G; Rapini, G; Serroni, N; Srinivasan, V; Tomasetti, C; Valchera, A | 1 |
| Petrova, MM; Piliugina, MS; Savchenko, AA; Shimohina, NY | 1 |
| Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB | 1 |
| Boulle, F; Franc, B; Gabriel, C; Kenis, G; Koedam, K; Lanfumey, L; Mocaer, E; Mongeau, R; Rognan, D; Steinbusch, HW; van den Hove, DLA; Velthuis, H | 1 |
| Alova, L; Atanasova, D; Atanasova, M; Kortenska, L; Lazarov, N; Nenchovska, Z; Stefanova, M; Tchekalarova, J | 1 |
| Abramova, LI; Nikiforova, IY; Novozhenova, TE; Oleichik, IV; Omelchenko, MA; Panteleeva, GP; Sorokin, SA; Subbotskaya, NV | 1 |
| Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E | 1 |
| Goodwin, GM | 1 |
| Hamon, M; Kasper, S | 1 |
| Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trahkt, I | 1 |
| Bourin, M; Prica, C | 1 |
| Rouillon, F | 1 |
| Mendlewicz, J | 1 |
| Blier, P | 1 |
| Brown, GM; Cardinali, DP; Pandi-Perumal, SR; Singh, J; Spence, DW; Srinivasan, V | 1 |
| Kozian, R; Syrbe, G | 1 |
| Bobrov, AS; Khamarkhanova, AA; Petrun'ko, OV; Shvetsova, AV | 1 |
| Somoskovi, C; Sumegi, A | 1 |
| Brown, GM; Brzezinski, A; Cardinali, DP; Pandi-Perumal, SR; Spence, DW; Srinivasan, V | 1 |
| David, DJ; Enhamre, E; Gabriel, C; Gardier, AM; Guilloux, JP; Hen, R; Mocaër, E; Rainer, Q; Xia, L | 1 |
| Dagyte, G; De Jager, T; Den Boer, JA; Gabriel, C; Luiten, PG; Mocaër, E; Van der Zee, EA | 1 |
| Arushanian, ÉB | 1 |
| Coogan, AN; Thome, J | 1 |
| Chancellor, D | 1 |
| Sapetti, A | 1 |
| Chutko, LS; Tursunova, KB | 1 |
| Molteni, R; Popoli, M; Racagni, G; Tardito, D | 1 |
| Acuña-Castroviejo, D; Lauterbach, EC; Othman, Z; Srinivasan, V; Zakaria, R | 1 |
| Vorob'eva, OV | 1 |
| Baldwin, DS; Bazire, S; Haddad, PM; McAllister Williams, RH; Sparshatt, A; Taylor, D; Taylor, P; Weston, E | 1 |
| Smirnova, VN; Tiuvina, NA | 1 |
| Appiani, F; Carroll, BT; De Ambrosi, B; Houser, J; Muñoz, C; Thomas, CJ; Viejo Sacha, MG | 1 |
| Burrows, GD; Hindmarch, I; Kennedy, SH; Lejoyeux, M; Montgomery, SA | 1 |
| Boyer, PA; de Bodinat, C; Delalleau, B; Mocaër, E | 1 |
| Wirz-Justice, A | 1 |
| Calabrese, JR; Guelfi, JD; Perdrizet-Chevallier, C | 1 |
| Baghai, TC; Eser, D; Möller, HJ | 1 |
| Popoli, M; Racagni, G; Riva, MA | 1 |
| Howland, RH | 1 |
19 review(s) available for s20098 and Depression, Endogenous
| Article | Year |
|---|---|
New insights on the antidepressant discontinuation syndrome.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Patient Compliance; Serotonin; Syndrome | 2014 |
[If the general practitioner has to decide: what is the evidence for the selection of antidepressants?].
Topics: Acetamides; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Duloxetine Hydrochloride; Evidence-Based Medicine; General Practice; Germany; Guideline Adherence; Humans; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
Topics: Acetamides; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Fibromyalgia; Humans; Migraine Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Schizophrenia; Sleep Wake Disorders | 2015 |
Innovation translates into antidepressant effectiveness.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Depressive Disorder, Major; Dopamine; Humans; Hypnotics and Sedatives; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin; Serotonin 5-HT2 Receptor Antagonists | 2009 |
Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
Topics: Acetamides; Aging; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Receptors, Melatonin; Signal Transduction; Sleep; Sleep Initiation and Maintenance Disorders; Suprachiasmatic Nucleus | 2009 |
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Delivery Systems; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index | 2009 |
Disruption of the circadian timing systems: molecular mechanisms in mood disorders.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Mood Disorders; Polymorphism, Genetic | 2009 |
Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs.
Topics: Acetamides; Benzofurans; Central Nervous System Depressants; Cyclopropanes; Depressive Disorder; Humans; Indenes; Jet Lag Syndrome; Melatonin; Sleep Disorders, Circadian Rhythm | 2010 |
[Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Drug Synergism; Humans; Hypnotics and Sedatives; Melatonin; Meta-Analysis as Topic; Receptors, Melatonin; Serotonin; Sleep Disorders, Circadian Rhythm | 2010 |
Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?
Topics: Acetamides; Animals; Benzodiazepines; Benzofurans; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder; Humans; Hypnotics and Sedatives; Indenes; Indoles; Melatonin; Sleep Initiation and Maintenance Disorders | 2011 |
[Melatoninergic antidepressant valdoxan].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Melatonin; Pineal Gland; Receptors, Melatonin; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Sleep | 2011 |
Chronotherapeutics and psychiatry: setting the clock to relieve the symptoms.
Topics: Acetamides; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain; Chronobiology Disorders; Chronotherapy; Circadian Rhythm; Depressive Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Seasonal Affective Disorder | 2011 |
Synergistic mechanisms involved in the antidepressant effects of agomelatine.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Agonists | 2012 |
Agomelatine in depressive disorders: its novel mechanisms of action.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Humans; Melatonin; Receptors, Melatonin; Sleep Wake Disorders | 2012 |
[Development of a new antidepressant : agomelatine].
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder; Disease Models, Animal; Humans; Hypnotics and Sedatives; Melatonin; Receptor, Serotonin, 5-HT2C | 2005 |
Biological rhythm disturbances in mood disorders.
Topics: Acetamides; Antidepressive Agents; Biological Clocks; Circadian Rhythm; Clinical Trials as Topic; Depressive Disorder; Drugs, Investigational; Humans; Melatonin; Phototherapy; Sleep Deprivation | 2006 |
Evidence of agomelatine's antidepressant efficacy: the key points.
Topics: Acetamides; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2007 |
The interaction between the internal clock and antidepressant efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Suprachiasmatic Nucleus | 2007 |
9 trial(s) available for s20098 and Depression, Endogenous
| Article | Year |
|---|---|
Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus.
Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Middle Aged; Pilot Projects; Self Care; Sertraline; Treatment Outcome; Young Adult | 2013 |
[A study of the efficacy and safety of valdoxan in the treatment of a depressive episode].
Topics: Acetamides; Adult; Antidepressive Agents; Computer Simulation; Depressive Disorder; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Prospective Studies | 2013 |
[Efficacy of agomelatine in depressive disorders with anxiety].
Topics: Acetamides; Adult; Aged; Anxiety; Depressive Disorder; Female; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study.
Topics: Acetamides; Adult; Depressive Disorder; Female; Fibromyalgia; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Serotonin Antagonists; Treatment Outcome | 2014 |
[Clinical predictors of the therapeutic response to valdoxan in moderate and severe depression].
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder; Female; Humans; Male; Middle Aged; Prognosis; Treatment Outcome; Young Adult | 2010 |
[Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study "Resonance"].
Topics: Acetamides; Adolescent; Adult; Aged; Cerebrovascular Disorders; Chronic Pain; Depressive Disorder; Female; Humans; Male; Middle Aged; Syndrome; Treatment Outcome; Young Adult | 2012 |
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
Topics: Acetamides; Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2004 |
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.
Topics: Acetamides; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Lithium Compounds; Male; Middle Aged; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome; Valproic Acid | 2007 |
Agomelatine: a novel atypical antidepressant.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Male | 2007 |
34 other study(ies) available for s20098 and Depression, Endogenous
| Article | Year |
|---|---|
Scaffold hopping of agomelatine leads to enhanced antidepressant effects by modulation of gut microbiota and host immune responses.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Brain; Cytokines; Depression; Depressive Disorder; Disease Models, Animal; Food Preferences; Gastrointestinal Microbiome; Immunity; Inflammasomes; Male; Mice; Mice, Inbred C57BL; Stress, Psychological; Treatment Outcome | 2020 |
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Citalopram; Clonazepam; Coronavirus Infections; COVID-19; Depressive Disorder; Female; Humans; India; Lorazepam; Male; Mirtazapine; Pandemics; Panic Disorder; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice.
Topics: Acetamides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Depressive Disorder; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Hippocampus; Humans; Memory Disorders; Mice; Microfilament Proteins; Nerve Tissue Proteins; Neuronal Plasticity; Stress, Psychological; Synapsins; Synaptophysin | 2017 |
Agomelatine-Related Shift to Mania in a Patient With Recurrent Depressive Disorder.
Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Recurrence | 2017 |
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; Young Adult | 2013 |
Agomelatine, melatonin and depressive disorder.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Humans; Melatonin | 2013 |
[Approaches to treatment optimization of depression in patients with Parkinson's disease].
Topics: Acetamides; Aged; Depressive Disorder; Female; Humans; Male; Middle Aged; Parkinson Disease | 2013 |
Agomelatine-induced gynaecomastia.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder; Gynecomastia; Humans; Male; Young Adult | 2013 |
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status.
Topics: Acetamides; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperature; Body Weight; Central Nervous System Depressants; Circadian Rhythm; Depressive Disorder; Fever; Fluoxetine; Hydrocortisone; Indoles; Male; Melatonin; Motor Activity; Norepinephrine; Pyridines; Serotonin 5-HT2 Receptor Antagonists; Stress, Psychological; Tupaiidae | 2014 |
Differential and converging molecular mechanisms of antidepressants' action in the hippocampal dentate gyrus.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Dentate Gyrus; Depressive Disorder; Disease Models, Animal; Fluoxetine; Gene Expression; Imipramine; Male; Neurons; Random Allocation; Rats, Wistar; Stress, Psychological; Thiazepines; Uncertainty | 2015 |
Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive tests.
Topics: Acetamides; Antidepressive Agents; Attention; Cognition; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Severity of Illness Index | 2014 |
Repeated restraint stress-induced atrophy of glutamatergic pyramidal neurons and decreases in glutamatergic efflux in the rat amygdala are prevented by the antidepressant agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Atrophy; Basolateral Nuclear Complex; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Glutamic Acid; Male; Neuronal Plasticity; Pyramidal Cells; Rats, Sprague-Dawley; Restraint, Physical; Stress, Psychological | 2015 |
[Clinical experience with agomelatine for the treatment of depression in elderly patients in outpatient practice].
Topics: Acetamides; Aged; Ambulatory Care; Depressive Disorder; Female; Humans; International Classification of Diseases; Male; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin Antagonists; Treatment Outcome | 2014 |
[An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders].
Topics: Acetamides; Acute Coronary Syndrome; Adult; Aged; Anxiety; Central Nervous System Depressants; Depressive Disorder; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2015 |
[Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit].
Topics: Acetamides; Acetylcarnitine; Aged; Antidepressive Agents; Apathy; Cyclohexanols; Depressive Disorder; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Behavioral and neurochemical characterization of TrkB-dependent mechanisms of agomelatine in glucocorticoid receptor-impaired mice.
Topics: Acetamides; Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Cell Proliferation; Depressive Disorder; Disease Models, Animal; Fear; Hippocampus; Male; Mice, Transgenic; Motor Activity; Receptor, trkB; Receptors, Glucocorticoid; Single-Blind Method; Social Behavior | 2016 |
Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats.
Topics: Acetamides; Adaptation, Ocular; Analysis of Variance; Animals; Body Weight; Depressive Disorder; Drug Administration Schedule; Exploratory Behavior; Food Preferences; Hippocampus; Hypnotics and Sedatives; Male; Maze Learning; Pineal Gland; Rats; Rats, Wistar; Serotonin; Swimming; Time Factors; Tritium | 2016 |
[Clinical and therapeutic perspectives of agomelatine (valdoxan) in the treatment of anhedonia in patients with endogenous depressions].
Topics: Acetamides; Adolescent; Adult; Anhedonia; Antidepressive Agents; Depressive Disorder; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Treatment Outcome; Young Adult | 2015 |
Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.
Topics: Acetamides; Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder; Drug Synergism; Male; Mianserin; Mice; Motor Activity; Piperidines; Swimming; Thiazepines | 2016 |
Agomelatine: innovation for the benefit of depressed patients.
Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Humans; Mood Disorders | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
The well of novel antidepressants: running dry.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder; Drug Industry; Humans; Research Design | 2010 |
[QTc prolongation during treatment with agomelatine].
Topics: Acetamides; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged | 2010 |
[Depression--sequelae of disturbed circadian rhythm. Rapid onset of effect supports treatment success].
Topics: Acetamides; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; Hypnotics and Sedatives; Secondary Prevention; Sleep Disorders, Circadian Rhythm | 2010 |
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cell Proliferation; Circadian Rhythm; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Mice, Inbred C57BL; Motor Activity; Neurogenesis; Neurons; Serotonin 5-HT2 Receptor Antagonists | 2012 |
Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain.
Topics: Acetamides; Animals; Antidepressive Agents; Brain Chemistry; Chronic Disease; Depressive Disorder; Disease Models, Animal; Male; Rats; Rats, Wistar; Stress, Psychological; Synapsins | 2011 |
The depression market.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Discovery; Humans; Melatonin | 2011 |
Agomelatine: an antidepressant without deterioration of sexual response.
Topics: Acetamides; Adult; Antidepressive Agents; Depression; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Libido; Male; Orgasm; Patient Satisfaction; Sexual Dysfunctions, Psychological; Treatment Outcome; Young Adult | 2012 |
[Depression: possible etiology: circadian dysregulation].
Topics: Acetamides; Antidepressive Agents; Depressive Disorder; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Randomized Controlled Trials as Topic; Sleep Disorders, Circadian Rhythm | 2012 |
[Emotional disorders in the pathogenesis of cervical headache].
Topics: Acetamides; Adult; Depressive Disorder; Headache Disorders; Humans; Male; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Young Adult | 2012 |
A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks.
Topics: Acetamides; Adult; Depressive Disorder; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outcome Assessment, Health Care; Patient Dropouts; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome; United Kingdom | 2013 |
[A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2012 |
Two cases of delirium with agomelatine therapy.
Topics: Acetamides; Adult; Aged, 80 and over; Antidepressive Agents; Delirium; Depressive Disorder; Female; Humans; Male; Treatment Outcome; Withholding Treatment | 2013 |
Agomelatine: AGO 178, AGO178, S 20098.
Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Design; Drug Evaluation, Preclinical; Drug Interactions; Humans | 2008 |